Methods for generating human arterial endothelial cells under defined conditions in the absence of insulin are described.

Provided are wild-type, S252W mutant-type, and P253R mutant-type FGFR2b extracellular segments and truncated proteins thereof, coding genes of the foregoing proteins, a recombinant vector comprising the genes, a host cell, a method for preparing the proteins, and a fusion protein of the proteins and an Fc segment. Also provided are applications of the proteins and a composition comprising the proteins in treating eczema, acne, psoriasis, skin allergy, seborrheic dermatitis, or seborrheic alopecia.

The technology relates in part to methods and compositions for ex vivo proliferation and expansion of epithelial cells.

Embodiments disclosed here provide engineered modified hematopoietic stem cells (HSCs), artificially prostaglandin E2 (PGE.sub.2)-stimulated HSCs, compositions comprising these HSCs, methods of using these modified HSCs for treating autoimmune diseases and disorders and for suppressing the immune system. In particular, the engineered modified HSCs or PGE.sub.2-stimulated HSCs express the surface marker, programmed cell death-1 ligand 1 (PD-L1).

The present invention relates to a method for culturing a 3-dimensional lung cancer organoid and a method for preparing a patient-derived xenograft animal model using the same. More specifically, the present invention relates to a method for culturing a 3-dimensional lung cancer organoid, a lung cancer organoid prepared by the method, a medium composition for culturing the lung cancer organoid, a method for preparing a xenograft animal model using the lung cancer organoid, a patient-derived lung cancer organoid xenograft animal model prepared by the method, and a method for analyzing therapeutic efficacy of an anticancer agent and a method for screening an anticancer agent, using the animal model.

Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.

The present invention relates to compositions and methods utilizing hair follicle derived Non-Bulbar Dermal Sheath cells for use in the treatment or prevention of the tendon injuries.

The present disclosure relates to a three-dimensional micro-environment structure for controlling cell behavior, a three-dimensional surface and an array for controlling cell behavior, and a method for manufacturing the three-dimensional micro-environment structure.

A method is described herein. The method includes: acquiring cells from a non-human animal source such as a tissue biopsy, stem cells, precursor cells, embryonic cells, bone marrow or any combination thereof after identification of immortalized cell lines, improvement of cell lines, or a spontaneous immortalization event; expanding cells from the non-human animal source in a plate or microfluidics chip to facilitate a formation of spheroids or organoids in a range of approximately 10 m to approximately 10 mm; harvesting the spheroids to initiate further propagation in adherent or suspension cultures; and/or seeding a bioreactor with the adherent or suspension cultures for scale-up of cultivated meat production. The method also includes screening the cells, spheroids, or organoids. The method also includes varying a composition of the spheroids to modify a density of the spheroids and/or properties of a meat product.

Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.